1261118-04-0

Basic information

• Product Name: 2-(4-fluorophenyl)-8,8-dimethyl-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one
• Synonyms: EOS-60852
• CAS NO: 1261118-04-0
• Molecular Formula: C₁₄H₁₄FN₃O
• Molecular Weight: 259.2788632
• Mol File: 1261118-04-0.mol

Chemical Properties

• Boiling Point: 541.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.31±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.18±0.40(Predicted)
• CAS DataBase Reference: 2-(4-fluorophenyl)-8,8-dimethyl-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-fluorophenyl)-8,8-dimethyl-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one(1261118-04-0)
• EPA Substance Registry System: 2-(4-fluorophenyl)-8,8-dimethyl-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one(1261118-04-0)

Safety Data

• Hazardous Substances Data: 1261118-04-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-fluorophenyl)-8,8-dimethyl-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one is used as a potential therapeutic agent for its potential antiviral, antifungal, and antitumor activities. Its unique structure with a fluorophenyl group and dimethyl substituent may contribute to its biological activity, making it a candidate for further research and development in the pharmaceutical field.
Used in Antiviral Applications:
In the field of virology, 2-(4-fluorophenyl)-8,8-dimethyl-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one is used as an antiviral agent, where its specific structure may interact with viral components, inhibiting viral replication and reducing the spread of infections.
Used in Antifungal Applications:
In the context of antifungal treatments, 2-(4-fluorophenyl)-8,8-dimethyl-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one is utilized for its potential to combat fungal infections, possibly by disrupting fungal cell functions or inhibiting essential fungal enzymes.
Used in Antitumor Applications:
2-(4-fluorophenyl)-8,8-dimethyl-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one is considered for use in antitumor applications, where it may exhibit properties that inhibit tumor growth or interfere with cancer cell proliferation, offering a potential avenue for cancer therapy.

Upstream product

• 1261118-03-9 C₂₄H₂₆FN₃O₄ 
• 1261118-02-8 C₂₀H₂₀FN₃O₂ 

Downstream Products

• 1261118-44-8 C₁₈H₂₁BrFN₃O 
• 1261118-45-9 C₁₈H₂₁FN₆O 
• 1261118-46-0 C₁₈H₂₃FN₄O 
• 1261118-08-4 C₂₃H₃₁FN₄O₃ 
• 1261117-75-2 C₂₃H₃₀BrFN₄O₃ 
• 1261115-67-6 2-amino-1-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one 
• 1261118-23-3 C₂₅H₂₈BrFN₄O 
• 1261118-24-4 C₂₅H₂₈FN₇O 
• 1261115-13-2 2-amino-1-(2-(4-fluorophenyl)-8,8-dimethyl-3-(p-tolylamino)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one 
• 1261115-69-8 2-amino-1-(3-(3,4-difluorophenylamino)-2-(4-fluorophenyl)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one 
• 1261117-85-4 C₁₄H₁₃BrFN₃O 
• 1261114-91-3 2-(4-fluorophenyl)-8,8-dimethyl-3-(p-tolylamino)-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one 
• 1261114-95-7 3-(4-chloro-3-fluorophenylamino)-2-(4-fluorophenyl)-8,8-dimethyl-7,8-dihydro imidazo[1,2-a]pyrazin-6(5H)-one 
• 1261113-99-8 2-(4-fluorophenyl)-8,8-dimethyl-N-p-tolyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-3-amine 

Relevant articles and documents

An efficient, stereocontrolled and versatile synthetic route to bicyclic partially saturated privileged scaffolds

Herein, we describe the development of a simple, high yielding and stereocontrolled strategy for the synthesis of a series of triazolopiperazines and other biologically relevant fused scaffolds from optically active amino acids. This route was applied to the synthesis of 22 scaffolds containing new, previously inaccessible vectors and used to access a novel analogue of ganaplacide.

Imidazolopiperazines: Lead optimization of the second-generation antimalarial agents

On the basis of the initial success of optimization of a novel series of imidazolopiperazines, a second generation of compounds involving changes in the core piperazine ring was synthesized to improve antimalarial properties. These changes were carried out to further improve the potency and metabolic stability of the compounds by leveraging the outcome of a set of in vitro metabolic identification studies. The optimized 8,8-dimethyl imidazolopiperazine analogues exhibited improved potency, in vitro metabolic stability profile and, as a result, enhanced oral exposure in vivo in mice. The optimized compounds were found to be more efficacious than the current antimalarials in a malaria mouse model. They exhibit moderate oral exposure in rat pharmacokinetic studies to achieve sufficient multiples of the oral exposure at the efficacious dose in toxicology studies.